The activity of cefmenoxime, an aminothiazolyl cephalosporin, was studied against 650 bacteria. It was slightly less active than cefotaxime and more active than moxalactam against staphylococci. It had activity similar to that of cefotaxime and ceftizoxime against group A and B streptococci and Streptococcus pneumoniae. It did not inhibit Streptococcus faecalis or Listeria spp. Cefmenoxime had activity similar to that of cefotaxime, ceftizoxime, ceftazidime, and moxalactam against Escherichia coli, Citrobacter diversus, Klebsiella, Proteus mirabilis, Salmonella, and Shigella. It inhibited ,3-lactamase-positive and -negative isolates at s0.4 pLg/ml. Cefmenoxime was somewhat less active than moxalactam or ceftizoxime against Enterobacter cloacae, Enterobacter aerogenes, and Enterobacter agglomerans, but was more active than cefotaxime, ceftizoxime, or ceftazidime against Morganella (minimum inhibitory concentration for 90% of isolates, 0.1 p.g/ml.), Proteus vulgaris and Providencia spp. It was as active as ceftizoxime was against Serratia. Pseudomonas spp. and Bacteroides spp. were relatively resistant (minimum inhibitory concentration for 90% of isolates, >100 ,ug/ml). The compound was stable to the common plasmid ,-lactamases, such as that of TEM. It was stable to most chromosomally mediated P-lactamases which act primarily as cephalosporinases, but was hydrolyzed by Bacteroides and Acinetobacter.
Cefmenoxime is an aminothiazolyl iminomethoxy cephalosporin with a methyl tetrazole side chain at position 3 of the dihydrothiazolidine ring (6, 9, 10) . Introduction of the methyl tetrazole group has increased the antibacterial activity of older cephalosporins and of cefoperazone and moxalactam (8, 12) . For this reason we were interested in comparing the in vitro activity of cefmenoxime with other aminothiazolyl cephalosporins, with cefoperazone and moxalactam, and also with aminoglycosides. We further wished to determine the ,B-lactamase stability and P-lactamase inhibitory activity of this agent. Fresh dilutions of the compounds were prepared daily in either sterile medium or distilled water. Bacterial isolates were obtained from patients hospitalized at the Columbia-Presbyterian Medical Center, New York, N.Y. In some experiments, the isolates tested were known to be multiply resistant to antibiotics or to contain P-lactamases. Some isolates had been stored frozen for a number of years.
MATERIALS AND METHODS
Antimicrobial activity was measured by an agar dilution method with Mueller-Hinton agar unless specified otherwise. A final inoculum of 10' colony-forming units (CFU), prepared by dilution of a fresh overnight broth culture, was applied to agar by a replicating spot device. Broth dilutions were performed with 10' CFU in tubes of 1-ml volume. Plates or tubes were incubated at 35°C for 18 h. The minimal inhibitory concentration (MIC) was defined as the lowest concentration of antibiotic that inhibited development of visible growth on agar or in broth. The minimal bactericidal concentration (MBC) was determined by plating 0.01-ml amounts from clear 1-ml broth tubes onto blood agar plates. The MBC was defined as the concentration at which there was no growth after 24 h of incubation at 35°C. The susceptibility of streptococci was determined by using Mueller-Hinton agar supplemented with 5% sheep blood. The susceptibility of Neisseria species and Haemophilus species was determined by culturing on chocolate Mueller-Hinton agar or in Levinthal broth and by incubation in the presence of 5% CO2. Anaerobic susceptibility was determined by using brucella agar supplemented with sheep blood and vitamin K. Anaerobic cultures were incubated for 48 h in GasPak jars (BBL Microbiology Systems).
Synergy studies were performed on agar by using serial twofold dilutions of both agents as previously described (4) . A fractional inhibitory concentration (FIC) index <0.5 was considered synergy and an FIC (11) . Antibiotic disks containing 30 ,ug of cefmenoxime or cefoxitin were placed contiguous to disks containing cefazolin (30 ,ug). The presence of 3-lactamase in isolates was determined by the nitrocefin assay (5). Stability to ,Blactamase was determined by a spectrophotometric assay which used the change in absorbance at the absorption maximum of each substrate as previously described (3). Inhibition of hydrolysis was determined by using either cephaloridine or nitrocefin as the substrate (2, 3) .
The inhibition assay with nitrocefin was performed with 10-' M nitrocefin in a final volume of 3 ml.
Enzyme and cefmenoxime at 10-4 M were incubated at 30°C for 10 min, and then nitrocefin was added. The change in absorbance at 482 nm was followed over 10 min in a temperature-controlled recording spectrophotometer. The change in absorbance of nitrocefin plus enzyme was followed as a control.
RESULTS
The activity of cefmenoxime against various bacteria is shown in Table 1 . Cefmenoxime inhibited 90% of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Morganella spp., Proteus rettgeri, and Salmonella spp., including Salmonella typhi, Shigella, and Citrobacter diversus at s0.2 ,ug/ ml. Among the Enterobacter spp. tested, there were isolates, particularly of Enterobacter cloacae and Enterobacter agglomerans, which were relatively resistant to cefmenoxime with MICs of 25 ,ug/ml. Although a few Serratia marcescens and Citrobacter freundii isolates also had MICs of 25 ,g/ml, the majority of strains had MICs below 6.3 ,ug/ml, as did Providencia. Pseudomonas aeruginosa, Pseudomonas maltophilia, other Pseudomonas spp., and Acinetobacter were relatively resistant, with MICs for 90% of isolates (MlCgo) of 2100 pg/ml.
The MIC for 50% of isolates (MIC50) for the Bacteroides fragilis group was 12.5 ,ug/ml, but the MIC90 was 100 ,ug/ml. These isolates included Bacteroides thetaiotamicron (MIC, 100 jg/ ml) and Bacteroides ovatus (MIC, 25 ,ug/ml). Among the gram-positive species tested, only Streptoccocus faecalis and Listeria spp. were resistant, with MICs 2100 ,ug/ml. Viridans streptococci varied in susceptibility, with some isolates having a cefmenoxime MIC .25 ,ug/ml. VOL. 22, 1982 on July 2, 2017 by guest http://aac.asm.org/ All of the Haemophilus and Neisseria isolates were inhibited by 0.5 ,ug/ml. were against group A, B, C, and G beta-hemo-zoxime against Morganella. Cefmenoxime was lytic streptococci, none of which has a 13-lacta-similar to the other new agents in activity against mase and for which the MIC90 was 0.05 ,ug/ml. Providencia. Cefmenoxime was similar in activiCefmenoxime had activity similar to cefotaxime ty to ceftizoxime against Serratia marcescens and ceftizoxime against Streptococcus pneumo-but was less active than ceftazidime. Cefmenoxniae. Cefmenoxime inhibited all of the cefaman-ime inhibited C. freundii isolates resistant to dole-resistant, ,-lactamase-containing Haemo-cefamandole and cefoxitin at concentrations philus influenzae isolates and was as active as similar to those agents. Against Pseudomonas ceftriaxone against this organism. The P-lacta-aeruginosa, cefmenoxime was no more active mase-positive Neisseria gonorrhoeae isolates than the other agents and much less active than were inhibited by similar concentrations of cef-ceftazidime. menoxime, cefotaxime, ceftizoxime, and cefEffect of test conditions. The type of medium triaxone. All of the cefamandole-resistant Esch-used had no major effect on the assays of erichia coli strains with cefoxitin MICs of 25 ,ug/ antibiotic activity. The presence of 50%o normal ml were inhibited by 0.4 ,ug of cefmenoxime per human serum did not alter the MIC for five ml, as were the isolates of K. pneumoniae. isolates each of Staphylococcus aureus, EscheAgainst the most resistant Enterobacter cloacae richia coli, Klebsiella spp., C. freundii, Morganisolates, moxalactam and ceftazidime were more ella spp., Enterobacter cloacae, Serratia, or active than cefmenoxime. In contrast, cefmen-Pseudomonas aeruginosa. The activity of the oxime was more active than cefotaxime or cefti-compound was not appreciably (more than dilu- (Table 5) .
Combination with other agents. Since cefmenoxime showed only minimal activity against Pseudomonas aeruginosa, it was combined with antipseudomonal penicillins and aminoglycosides. Synergy was found for 93% of the isolates tested with the cefmenoxime-piperacillin combination and 63% of those tested with the ticarcillin-cefmenoxime combination. Synergy was found for all of the isolates tested with the gentamicin-cefmenoxime combination. Of note was the fact that no antagonism was found when the penicillins were combined with cefmenoxime. Among these strains of Pseudomonas aeruginosa, five showed antagonism when cefoxitin was combined with piperacillin or ticarcillin (Table 6) .
To determine the effect of cefmenoxime as an DISCUSSION Cefmenoxime is similar in chemical structure to cefotaxime, ceftizoxime, and ceftriaxone since it contains an aminothiazolyl side chain and an iminomethoxy group. However, cefmenoxime possesses a methyl tetrazole group on the dihydrothiazine ring such as is present in cefamandole, cefoperazone, and moxalactam. In these latter agents, this group has caused increased activity against certain gram-negative bacteria (8, 12) . This study shows that cefmenoxime has an antibacterial spectrum similar to cefotaxime, ceftizoxime, ceftazidime, and moxalactam against most of the Enterobacteriaceae. Its activity against gram-positive organisms was lower than that of the earlier cephalosporins, particularly against Staphylococcus aureus, and it does not inhibit methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis. It shows minimal differences between MIC50 and MIC90 values for Escherichia coli, K. pneumoniae, and Proteus species. There was an inoculum effect with certain Enterobacter, Serratia, and Pseudomonas species which contain chromosomal cephalosporinases. This has been noted with other agents of this chemical class and with moxalactam as well (1, 2) .
Its stability to P-lactamases makes it as active as these other agents against Haemophilus, Neisseria, and other Enterobacteriaceae which contain plasmid P-lactamases, but its instability to attack by the j-lactamases of Bacteroides and Acinetobacter probably explains its lower activity against these bacteria.
Cefmenoxime does not induce ,-lactamase activity as does cefoxitin but acts as an effective inhibitor of some chromosomal cephalosporin-VOL. 22, 1982 on July 2, 2017 by guest http://aac.asm.org/ Downloaded from ases, as we have shown earlier for cefotaxime and moxalactam (1, 2) .
These properties of cefmenoxime make it comparable to the other agents of this class. Our results show somewhat higher MICs than those published (6, 9, 12) , undoubtedly due to our selection of P-lactamase-producing isolates; however, this probably gives a better reflection of the activity of the compound against highly resistant bacteria.
